Safety and Effectiveness of Indwelling Percutaneous Drainage in Hospitalized Terminally Ill Cancer Patients with Recurrent Ascites

Kwonoh Park, Geon Woo Lee, Jae-Joon Kim, Sang-Bo Oh, So Yeon Oh, Eun-Ju Park, Jin Hyeok Kim, Joo Yeon Jang, Ung-Bae Jeon

Medical Oncology and Hematology, Departments of Internal Medicine, Family Medicine, and Radiology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea

Objectives: Terminally ill cancer patients in hospice palliative care unit are reluctant to undergo repetitive invasive procedures due to coagulopathies and poor performance or condition, while catheter management such as regular irrigation during hospitalization is easy. The purpose of this study was to investigate the safety and efficacy of indwelling intraperitoneal (IP) catheter in hospitalized terminally ill cancer patients with recurrent ascites.

Methods: A retrospective review was conducted in patients who underwent IP catheter at the hospice palliative care unit of Pusan National University Yangsan Hospital between August 2016 and June 2018. All catheters were inserted by interventional radiologists with radiological guidance. The primary end-points were functional IP catheter maintenance rate, which is catheter maintained with patency for drainage until the intended time.

Results: A total of 25 terminally ill cancer patients underwent IP catheters placements during the study period. All catheters were successfully inserted without major complications, but one patient had trivial bleeding and one other patient had temporary pain. The median time from admission to catheter insertion was 5 days (range, 1 to 49 days). Twenty-one catheters were maintained with function until the intended time, three cases were maintained without function, and the last one was removed early due to obstruction and pain. Finally, the functional IP maintenance rate was 84% (21/25) and the median functional catheter life span was 15 days (95% confidence interval, 10.8 to 17.2).

Conclusion: Our study showed relatively favorable results for IP catheter maintenance and safety in hospitalized terminally ill cancer patients with malignant ascites.

Introduction

Recurrent ascites is a known representative complication for advanced cancer patients, it’s frequency is known to increase with progressing terminal status in approximately 6% to 10% of patients admitted to hospice palliative care (HPC) units [1]. Symptoms of ascites include pain from tense abdominal extension, nausea and vomiting, reflux esophagitis, respiratory difficulty from diaphragmatic splinting, lower extremity edema, decreased mobility and consequent reduction in quality of life (QoL) [2–4]. Medical treatments using sodium restriction and diuretics are primarily applied for controlling the ascites–related...
symptoms [5], but the ascites are not amenable to medical treatment in some patients, eventually repeated paracentesis is widely used for palliation of symptomatic malignant ascites [2,3,6]. However, intermittent paracentesis has a limitation that there is short-term ascites related symptom relief due to rapid re-accumulation, thus leads to frequent repetitive procedures [2,5]. Additionally, repeated paracentesis has a small, but well-defined risk of catastrophic complications including bowel perforation, internal bleeding, or hypotension, as well as trivial complications such as pain or minor bleeding every time a needle is inserted. Clinicians often wait until fluid accumulation is substantial to avoid these risks, and to ensure the ascites is amenable to drainage, resulting in a deterioration in patient QoL [7].

The indwelling intraperitoneal (IP) catheter is an untunneled catheter that can be easily inserted, and can provide durable and effective symptom relief using daily consecutive drainage, avoiding the hazards and disadvantages related to repeated procedures [8–10]. Although there are limitations such as cumbersome catheter management, inconvenience in activities, and relatively short duration of functioning [11], indwelling IP catheters can be a logical choice for controlling ascites-related symptoms in hospitalized terminally ill cancer patients with a limited lifetime of 1 to 2 months and limited activity [12].

Although the practice of indwelling IP catheters is not a new technique [8–11,13], there are scanty data documenting the safety and efficacy of such a technique, especially in hospitalized terminally ill cancer patients [8]. Thus, we investigated the safety and efficacy of indwelling IP catheters in hospitalized terminally ill cancer patients with refractory ascites.

Methods

1. Patients and study design

Terminally ill cancer patients who underwent indwelling IP catheter placement for palliation of refractory malignant ascites in the HPC unit at Pusan National University Yangsan Hospital between August 2016 and June 2018 were enrolled in this study. A terminally ill cancer patient receives no additional anticancer treatment, and has an estimated survival time of less than 1 to 2 months. Of these patients, enrolled patients were as follows: 1) needed paracentesis more than twice a week, 2) without severe coagulopathies with platelet count less than 50,000/mm$^3$ or international normalized ratio higher than 2, and 3) without severe behavioral problems which would make IP catheter insertion difficult. This study was approved by our institutional review board of Pusan National University Yangsan Hospital (05-2019-054), which waived the requirement for informed consent due to the retrospective design of this study.

2. IP catheter insertion procedure and management

All IP catheters were inserted by an interventional radiologist in the angiography room using ultrasound guidance or fluoroscopic imaging. All operators wore aseptic gowns, masks, and gloves, and all the patients received a dressing with aseptic drapes. Seldinger’s technique and trocar access were routinely used. The catheter lines were 8.5 French lumens and were made of second/third-generation polyurethane. The insertion site was the left lower quadrant of the abdomen lateral to the course of the inferior epigastric vessels. The catheters were sutured and they were held in place with a catheter fixation device. The tubes were clamped during transfer from the radiology suite to the ward, as a large volume can be unknowingly removed if the patient is left unattended and there is a delay in transport. The technical success of IP catheter insertion was defined as when ascites was draining through the correctly placed catheter without acute catastrophic complication.

No patient was administered prophylactic antibiotics or anticoagulation drugs for infection or thrombosis. All of the patients received a closed dressing dampened with betadine on the catheter insertion site every 3 days. Saline flushing followed by 10 mL of saline was performed every two or three times a day. Drainage was performed 500 to 2,000 mL per day rather than continuous drainage and re-locked when the target volume was drained.

3. Catheter monitoring and data collection

We checked daily ascites drainage amounts and catheter patency using saline irrigation. And we reviewed medical records related with complications, including pain, edema, bleeding, cellulitis and local or systemic catheter-related infections. Delayed complications were catheter-related infection such as cellulitis or peritonitis, catheter dislodgement, and obstruction. Peritonitis was defined as clinical symptoms such as abdominal pain or fever with positive ascites or blood culture. Catheter
obstruction was suspected when the catheter flow was im-
possible to back flush with drainage, and it was diagnosed by
confirming residual ascites using physical examination or ultra-
sound. In this case, unless other acute complications developed,
we waited for drainage recovery drainage using catheter saline
irrigation for 48 hours. When drainage was not recovered,
catheter repositioning or change was attempted considering
ascites symptoms and life expectancy. On the other hand, if
catheter function was lost but the procedure was difficult to
perform due to deteriorated performance, or if the patient did
not complain of discomfort associated with the catheter itself,
the catheter without function was retained. Functional catheter
status was defined as adequate drainage without complications
leading to catheter removal.

4. Statistical analysis
We summarized baseline demographics and IP catheter-
related characteristics using descriptive statistics, including
medians, means, and ranges. The primary end points were
functional IP catheter maintenance rate, which was defined as
IP catheter maintained with patency until the intended time
(discharge, transfer, or death), and functional IP catheter life
span, which was calculated from the insertion date to the last
date of drainage and was assessed using Kaplan–Meier es-
timates. The secondary endpoints were IP catheter insertion
success rate, premature removal rate, and complication rate.
The complication and premature removal rates were reported
as complications per 1,000 IP catheter days and a simple rate.
Statistical analyses were performed using SPSS ver. 17.0 (SPSS
Inc., Chicago, IL, USA).

Results
1. Patients and characteristics
In total, 25 terminally ill cancer patients were enrolled in this
study during the study period and a total of 503 IP catheter
days were analyzed. Patient median age was 62 years (range,
36 to 76 years), and 15 patients (60%) were male. Seventeen
cases (68%) had a Karnofsky Performance Scale score of 40
or less (Table 1). The median time from admission to hospice–
palliative unit to IP catheter insertion was 5 days (range, 1 to 49
days). By the time of the analysis (September 2018), the median
survival time from admission to hospice–palliative unit to death
or the last follow–up was 27 days (95% confidence interval
[CI], 24.1 to 29.9; range, 7 to 92) to disease burden on image
studies, 18 patients showed definitive peritoneal or omental le-
sions such as nodular or thickening lesions, while the remaining
seven patients showed only liver or intraabdominal lymph node
metastasis without definitive peritoneal seeding. The analysis
of ascites showed its nature was serous (12, 60%) and bloody
(8, 40%) out of 20 patients available for ascites analysis, and
malignant cells were identified in 6 (38%) out of 16 patients by
checked cytology or cell–block (Table 2).

2. IP catheter efficacy
All catheters were successfully inserted in two patients with
trivial complications (bleeding and pain). No catastrophic
complications such as viscus perforation or excessive bleeding
were encountered during tube insertion and adequate drainage.
So, the success rate for IP catheter insertion was 100%.

Twenty–one of the 25 cases had functional catheter until the
intended time (discharge, transfer, or death): 16 cases main-
tained their catheter until death, and five cases were transferred
to another palliative care hospital. The remaining four patients

| Table 1. Baseline patient characteristics (n=25) |
|---------------------------------------------|
| Characteristics               | Value |
| Age (yr)                      | 62 (36–76) |
| Sex                          |          |
| Male                         | 15 (60)  |
| Female                       | 10 (40)  |
| Primary cancer type          |          |
| Gastric cancer               | 5 (20)   |
| Biliary tract cancer         | 11 (44)  |
| Pancreas cancer              | 6 (24)   |
| Breast cancer                | 2 (8)    |
| Ovary cancer                 | 1 (4)    |
| Disease presentation status  |          |
| Initially metastatic status  | 18 (72)  |
| Recurrent status             | 7 (28)   |
| Karnofsky Performance Scale  |          |
| 50–60                        | 8 (32)   |
| 30–40                        | 14 (56)  |
| 10–20                        | 3 (12)   |

Values are presented as median (range) or number (%).
were maintained without catheter function (three patients) or the catheter was removed (one patient). Thus, the functional catheter maintenance success rate was 84%, and the median functional catheter life span was 15 days (95% CI, 9.5 to 20.5; range, 2 to 68) (Table 3).

3. IP catheter complications and removal

Eleven complications (21.8/1,000 catheter days) occurred with the 25 episodes of catheterization. The most frequently documented complications were catheter obstruction in five cases (20%, 9.94/1,000 catheter days), followed by pain in three cases (12%, 5.96/1,000 catheter days), and leakage, bleeding and insertion site cellulitis in one case (4%, 2.0/1,000 catheter days) (Table 4). Of the five patients who developed obstruction, the catheter was immediately removed in one patient due to associated infection, four patients underwent tube changes with a large size catheter of 10.2 French. However, only one patient’s catheter was functional until the end-time. The remaining three patients developed catheter obstruction again. There was no IP catheter complication–related death.

Discussion

The current study was conducted to evaluate the safety and efficacy of indwelling IP catheters in homogenous hospitalized terminally ill cancer patients in HPC. All IP catheters were inserted safely and the functional IP catheter maintenance rate
was 84%, showing acceptable results. Considering characteristics of hospitalized terminally ill cancer patients who have short life expectancy and poor general condition, IP catheters may be used to manage the symptoms caused by refractory ascites with an acceptable safety profile. To our knowledge, this is the first study to investigate indwelling IP catheters in hospitalized HPC patients.

For the management of refractory ascites, three invasive methods using permanent or long-term devices have been applied and studied as follows: tunneled catheters [14–17], peritoneal ports [18–21], and IP catheters [9–11]. The tunneled catheter or peritoneal port have the advantage of being able to be used over a permanent or long-term period, but there is a complication risk including wound dehiscence because a complicated procedure is needed for the insertion process [12,14]. Therefore, it is not appropriate for terminally ill cancer patients, because they have a limited life expectancy of less than 1 to 2 months and the risk of delayed wound healing due to poor general status. On the other hand, indwelling IP catheters as untunneled catheters can be easily inserted [12]. However, there are limitations for patient activity due to the risk of catheter dislodgement, and the need for proper management such as frequent irrigation to prevent complications considering the relatively high risk of infection or obstruction [8,11]. The indwelling IP catheter has mainly been used only in hospitalized patients due to its restriction on activities of daily life and a shorter dwelling durability, so there are scanty data except three prior studies [9–11], unlike other tunneled catheters or ports. However, in the case of terminally ill cancer patients admitted to the HPC unit, proper catheter management is relatively easy due to admission status, limited activity which reduces the risk of catheter dislodgement, the limited survival duration of 1 to 2 months reduces the likelihood of catheter-related complications which increase with longer dwelling time, and their well-tolerated insertion procedure. Considering the limited life expectancy of such patients, managements of refractory ascites should be minimally invasive with maintaining effectiveness. The ideal treatment should aim to control symptoms and improve QoL with the least patient discomfort. Thus, indwelling IP catheters are the best option for hospitalized terminally ill cancer patients with refractory ascites, and the results of our study support this notion.

The loss of catheter function, such as obstruction and premature removal, was 16%, which is less than the 35% reported in a previous study [11]. It is possible that our patients in HPC settings were less likely to receive strict work-ups for clinical problems including fever. Further, the retrospective design of this study resulted in less detection of complications. On the other hand, catheter management in these hospitalized patients was relatively good because of catheter management including frequent irrigation by a healthcare provider rather than self-care by themselves. Additionally, as expected, limited survival duration after catheter insertion (median, 19 days; 95% CI, 8.6 to 29.4) may contribute to a reduced possibility of catheter-related complications. For example, considering that the median time for development of catheter-related infection and obstruction, which were the most common complications in previous studies, were 42 and 25 days, respectively [11], a short survival duration in this study may serve as a basis for explaining the low incidence of complications. This is more evidence that indwelling IP catheters may be more effective for patients in HPC settings.

The current study had several limitations due to its retrospective design. First, relatively definitive complications were likely to be clearly identified, but trivial complications such as pain or leakage might be missing. For example, in the case of complications such as leakage, 4% to 10% of tunneled catheters developed leakage [15,16], but only 4% in this study, which suggests a limitation due to the retrospective design. However, since all patients were in admitted status, the obstructions and infections that were most important for functional catheter maintenance were relatively accurately identified through daily check-ups. Second, patient-reported outcomes such as symptom improvement or QoL would be of critical importance for evaluating IP catheters in standard practice, but they could not be checked in the current study.

Despite these limitations, this study is the first to investigate the indwelling IP catheter in homogeneous hospitalized HPC patients with specific characteristics. However, the successful management of malignant ascites using IP catheters is most likely multifactorial, and dependent on underlying malignancy, catheter thickness, procedure, and operator experience, performance status, and comorbidities. Thus, to clarify the management strategies for malignant ascites using indwelling IP catheters, future prospective clinical trials to investigate adequate catheter thickness according to characteristics of the ascites...
(e.g., serum ascites albumin gradient levels), most appropriate time for catheter insertion, and patient-reported outcomes are needed.

References

1. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites: clinical and experimental observations. *Ann Surg* 1986;203:644-651.
2. Eason AM, Bezjak A, Ross S, Wright JG. The ability of existing questionnaires to measure symptom change after paracentesis for symptomatic ascites. *Ann Surg Oncol* 2007;14:2348-2357.
3. Day R, Mitchell T, Keen A, Perkins P. The experiences of patients with ascites secondary to cancer: a qualitative study. *Palliat Med* 2013;27:739-746.
4. Husain A, Bezjak A, Eason A. Malignant ascites symptom cluster in patients referred for paracentesis. *Ann Surg Oncol* 2010;17:461-469.
5. Becker G, Galandi D, Blum HE. Malignant ascites: systematic review and guideline for treatment. *Eur J Cancer* 2010;42:589-597.
6. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. *J Pain Symptom Manage* 1998;16:96-101.
7. Keen A, Fitzgerald D, Bryant A, Dickinson HO. Management of drainage for malignant ascites in gynaecological cancer. *Cochrane Database Syst Rev* 2010:CD007794.
8. Fleming ND, Alvarez-Secord A, Von Gruenigen V, Miller MJ, Abernethy AP. Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review. *J Pain Symptom Manage* 2009;38:341-349.
9. Mercadante S, Intravaia G, Ferrera P, Villari P, David F. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. *Support Care Cancer* 2008;16:973-978.
10. Gu X, Zhang Y, Cheng M, Liu M, Zhang Z, Cheng W. Management of non-ovarian cancer malignant ascites through indwelling catheter drainage. *BMC Palliat Care* 2016;15:44.
11. Lee A, Lau TN, Yeong KY. Indwelling catheters for the management of malignant ascites. *Support Care Cancer* 2000;8:493-499.
12. Stukan M. Drainage of malignant ascites: patient selection and perspectives. *Cancer Manag Res* 2017;9:115-130.
13. Belfort MA, Stevens PJ, DeHaek K, Soetens R, Krige JE. A new approach to the management of malignant ascites: a permanently implanted abdominal drain. *Eur J Surg Oncol* 1990;16:47-53.
14. Lungren MP, Kim CY, Stewart JK, Smith TP, Miller MJ. Tunneled peritoneal drainage catheter placement for refractory ascites: single-center experience in 188 patients. *J Vasc Interv Radiol* 2013;24:1303-1308.
15. Maleux G, Indesteege I, Laenen A, Verslype C, Vergote I, Prene H. Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome. *Radio Oncol* 2016;50:197-203.
16. Tapping CR, Ling L, Razack A. PleurX drain use in the management of malignant ascites: safety, complications, long-term patency and factors predictive of success. *Br J Radiol* 2012;85:623-628.
17. Richard HM 3rd, Coldwell DM, Boyd-Kranis RL, Murthly R, Van Echo DA. PleurX tunneled catheter in the management of malignant ascites. *J Vasc Interv Radiol* 2001;12:373-373.
18. Monsky WL, Yoneda KY, MacMillan J, Deutsch LS, Dong P, Horigan H, et al. Peritoneal and pleural ports for management of refractory ascites and pleural effusions: assessment of impact on patient quality of life and hospice/home nursing care. *J Palliat Med* 2009;12:811-817.
19. Coupe NA, Cox K, Clark K, Boyer M, Stockler M. Outcomes of permanent peritoneal ports for the management of recurrent malignant ascites. *J Palliat Med* 2013;16:938-940.
20. Ozkan O, Akinci D, Gocmen R, Cil B, Ozmen M, Akhan O. Percutaneous placement of peritoneal port-catheter in patients with malignant ascites. *Cardiovasc Intervent Radiol* 2007;30:232-236.
21. Savin MA, Kirsch MJ, Romano WJ, Wang SK, Arpasi PJ, Mazon CD. Peritoneal ports for treatment of intractable ascites. *J Vasc Interv Radiol* 2005;16:363-368.